Thryv Therapeutics Embarks on Pivotal Phase 2/3 Long QT Study with THRV-1268 Thryv Therapeutics has launched a pivotal Wave II clinical study examining THRV-1268, an oral SGK1 inhibitor for Long QT Syndrome Type 2. This study aims to advance treatment options for this serious condition.

Thryv Therapeutics Embarks on Pivotal Phase 2/3 Long QT Study with THRV-1268 #Canada #Montreal #Thryv_Therapeutics #Long_QT_Syndrome #THRV-1268

Thryv Therapeutics Secures FDA Approval for THRV-1268 to Combat Long QT Syndrome Thryv Therapeutics has received FDA IND clearance for THRV-1268, a significant step towards addressing Long QT Syndrome with upcoming clinical trials.

Thryv Therapeutics Secures FDA Approval for THRV-1268 to Combat Long QT Syndrome #Canada #Montreal #Thryv_Therapeutics #Long_QT_Syndrome #THRV-1268

Thryv Therapeutics to Showcase Promising Cardiac Research at 2025 ESC Congress in Madrid Thryv Therapeutics is set to present groundbreaking preclinical data at the upcoming European Society of Cardiology Congress 2025 in Madrid, Spain.

Thryv Therapeutics to Showcase Promising Cardiac Research at 2025 ESC Congress in Madrid #Canada #Montreal #Thryv_Therapeutics #SGK1_inhibitors #Long_QT_Syndrome

Thryv Therapeutics to Share Innovative Clinical Findings at Healthcare Conferences in New York Thryv Therapeutics, a biotechnology firm, will present recent findings on SGK1 inhibitors at major healthcare investor events in New York City, showcasing exciting developments.

Thryv Therapeutics to Share Innovative Clinical Findings at Healthcare Conferences in New York #Canada #Montreal #Thryv_Therapeutics #SGK1_inhibitors #Long_QT_Syndrome

Thryv Therapeutics Set to Showcase Innovations at 2025 Piper Sandler Virtual Cardio Day Thryv Therapeutics is excited to participate in the 2025 Piper Sandler Virtual Cardio Day, highlighting their advancements in cardiovascular treatments.

Thryv Therapeutics Set to Showcase Innovations at 2025 Piper Sandler Virtual Cardio Day #Canada #Montreal #Thryv_Therapeutics #SGK1_inhibitors #Long_QT_Syndrome